FDA Approves New Topical Antifungal Luliconazole 1%

November 16, 2013, 10:52 am

≫ Next: 10-Bagger Returns Without R&D

≪ Previous: Endo Tax Edge for Deals Mimics Valeant Playbook: Real M&A

$

0

0

FDA Approves New Topical Antifungal Luliconazole 1%

Medscape

---

10-Bagger Returns Without R&D

November 24, 2013, 9:31 am

≫ Next: Valeant Pharmaceuticals Agrees to Acquire Solta Medical for $2.92 Per Share in Cash

≪ Previous: FDA Approves New Topical Antifungal Luliconazole 1%

$

0

0

10-Bagger Returns Without R&D

Motley Fool

Valeant Pharmaceuticals Agrees to Acquire Solta Medical for $2.92 Per Share in Cash

December 16, 2013, 5:24 am

≫ Next: Not all pharmaceuticals are created equal

≪ Previous: 10-Bagger Returns Without R&D

$

0

0

Valeant Pharmaceuticals Agrees to Acquire Solta Medical for $2.92 Per Share in Cash

Yahoo

Not all pharmaceuticals are created equal

December 26, 2013, 10:56 am

≫ Next: Jazz, Valeant Join Drug Makers' Q4 Merger Rush

≪ Previous: Valeant Pharmaceuticals Agrees to Acquire Solta Medical for $2.92 Per Share in Cash

$

0

0

Not all pharmaceuticals are created equal

Marketwatch

Jazz, Valeant Join Drug Makers' Q4 Merger Rush

December 30, 2013, 4:26 pm

≫ Next: Pfizer Is Old News, But Valeant Isn't

≪ Previous: Not all pharmaceuticals are created equal

$

0

0

Jazz, Valeant Join Drug Makers' Q4 Merger Rush

Investors.com

Pfizer Is Old News, But Valeant Isn't

January 3, 2014, 8:43 am

≫ Next: 22 Biotech Stock Predictions for 2014

≪ Previous: Jazz, Valeant Join Drug Makers' Q4 Merger Rush

$

0

0

Pfizer Is Old News, But Valeant Isn't

Seeking Alpha

22 Biotech Stock Predictions for 2014

January 6, 2014, 6:47 am

≫ Next: Valeant seeks to become top 5 pharmaceutical company -CEO

≪ Previous: Pfizer Is Old News, But Valeant Isn't

$

0

0

22 Biotech Stock Predictions for 2014

TheStreet.com

Valeant seeks to become top 5 pharmaceutical company -CEO

January 7, 2014, 7:09 am

≫ Next: Valeant Dreams Big; Cancer Drug News Lifts Pharmacyclics

≪ Previous: 22 Biotech Stock Predictions for 2014

$

0

0

Valeant seeks to become top 5 pharmaceutical company -CEO

Yahoo/Reuters

---

Valeant Dreams Big; Cancer Drug News Lifts Pharmacyclics

January 8, 2014, 5:05 am

≫ Next: Valeant, Actavis, Mylan eye Pfizer's generics unit

≪ Previous: Valeant seeks to become top 5 pharmaceutical company -CEO

$

0

0

Valeant Dreams Big; Cancer Drug News Lifts Pharmacyclics

Yahoo/Investors Business Daily

Valeant, Actavis, Mylan eye Pfizer's generics unit

January 14, 2014, 7:06 am

≫ Next: Valeant Pharmaceuticals to Acquire Precision Dermatology for $475 Million

≪ Previous: Valeant Dreams Big; Cancer Drug News Lifts Pharmacyclics

$

0

0

Valeant, Actavis, Mylan eye Pfizer's generics unit

Reuters

Valeant Pharmaceuticals to Acquire Precision Dermatology for $475 Million

February 3, 2014, 6:23 am

≫ Next: Actavis-Forest Bid Shines Light on Valeant Next: Real M&A

≪ Previous: Valeant, Actavis, Mylan eye Pfizer's generics unit

$

0

0

Valeant Pharmaceuticals to Acquire Precision Dermatology for $475 Million

Fierce Pharma

Actavis-Forest Bid Shines Light on Valeant Next: Real M&A

February 19, 2014, 8:18 am

≫ Next: Valeant swings to profit on Bausch & Lomb buy

≪ Previous: Valeant Pharmaceuticals to Acquire Precision Dermatology for $475 Million

$

0

0

Actavis-Forest Bid Shines Light on Valeant Next: Real M&A

Bloomberg

Valeant swings to profit on Bausch & Lomb buy

February 27, 2014, 5:17 am

≫ Next: Drugmakers Actavis, Biogen, Valeant Hold Near Highs

≪ Previous: Actavis-Forest Bid Shines Light on Valeant Next: Real M&A

$

0

0

Valeant swings to profit on Bausch & Lomb buy

Yahoo/Reuters

Drugmakers Actavis, Biogen, Valeant Hold Near Highs

March 4, 2014, 7:17 pm

≫ Next: Valeant CEO Seeks Acquisitions in High-Growth Health Care

≪ Previous: Valeant swings to profit on Bausch & Lomb buy

$

0

0

Drugmakers Actavis, Biogen, Valeant Hold Near Highs

Investors.com

Valeant CEO Seeks Acquisitions in High-Growth Health Care

March 19, 2014, 12:47 pm

≫ Next: Valeant Targets Corporate ‘Fat’ in Push for Big Leagues

≪ Previous: Drugmakers Actavis, Biogen, Valeant Hold Near Highs

$

0

0

Valeant CEO Seeks Acquisitions in High-Growth Health Care

Bloomberg

---

Valeant Targets Corporate ‘Fat’ in Push for Big Leagues

March 20, 2014, 6:31 am

≫ Next: Novartis to Shire Said to Weigh Bids for ThromboGenics

≪ Previous: Valeant CEO Seeks Acquisitions in High-Growth Health Care

$

0

0

Valeant Targets Corporate ‘Fat’ in Push for Big Leagues

Bloomberg

Novartis to Shire Said to Weigh Bids for ThromboGenics

April 14, 2014, 3:49 pm

≫ Next: Top 10 Pharma M&A deals of 2013

≪ Previous: Valeant Targets Corporate ‘Fat’ in Push for Big Leagues

$

0

0

Novartis to Shire Said to Weigh Bids for ThromboGenics

Bloomberg

Top 10 Pharma M&A deals of 2013

April 17, 2014, 5:29 am

≫ Next: Billionaire Bill Ackman, Valeant Want To Takeover Botox-Maker Allergan

≪ Previous: Novartis to Shire Said to Weigh Bids for ThromboGenics

$

0

0

Top 10 Pharma M&A deals of 2013

Fierce Pharma

Billionaire Bill Ackman, Valeant Want To Takeover Botox-Maker Allergan

April 21, 2014, 2:03 pm

≫ Next: With Big Pharma In Retreat, Ackman And Novartis Try A New Blueprint For Drug Companies

≪ Previous: Top 10 Pharma M&A deals of 2013

$

0

0

Billionaire Bill Ackman, Valeant Want To Takeover Botox-Maker Allergan

Forbes

With Big Pharma In Retreat, Ackman And Novartis Try A New Blueprint For Drug Companies

April 22, 2014, 6:51 am

≫ Next: Novartis, Valeant bids herald new deal-making era for pharma

≪ Previous: Billionaire Bill Ackman, Valeant Want To Takeover Botox-Maker Allergan

$

0

0

With Big Pharma In Retreat, Ackman And Novartis Try A New Blueprint For Drug Companies

Forbes